KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

2,477
Mkt Cap
$2.87B
Volume
402,062.00
52W High
$39.79
52W Low
$17.82
PE Ratio
943.31
KNSA Fundamentals
Price
$38.77
Prev Close
$38.90
Open
$38.87
50D MA
$36.31
Beta
0.72
Avg. Volume
440,054.38
EPS (Annual)
-$0.6047
P/B
5.80
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again
Kiniksa Pharmaceuticals International, plc (KNSA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·10d ago
News Placeholder
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Zacks·18d ago
News Placeholder
Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks·18d ago
News Placeholder
Beat the Market the Zacks Way: Helios Technologies, InterDigital, UnitedHealth in Focus
Helios Technologies, InterDigital and UnitedHealth shine as Zacks' strategies deliver strong gains across model portfolios.
Zacks·25d ago
News Placeholder
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
Zacks·28d ago
News Placeholder
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
Zacks·29d ago
News Placeholder
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Zacks·29d ago
News Placeholder
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
Zacks·30d ago
News Placeholder
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.
Zacks·30d ago

Latest KNSA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.